Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06225232

Psilocybin in the Treatment of Cannabis Use Disorder: A-Proof-of-Concept Study

An 8-week Phase 2 Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Psilocybin-assisted-psychotherapy in Adults With Cannabis Use Disorder: A Proof-of-Concept Study

Status
Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
16 (estimated)
Sponsor
McMaster University · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

Cannabis is the most commonly used psychoactive substance in Canada (Lowry \& Corsi, 2020). A sub-group of cannabis users develop a condition known as Cannabis Use Disorder (CUD), which is defined as a regular pattern of cannabis use that causes performance difficulty at work, school and relationships (Hasin et al., 2013). A review of current treatments available for CUD indicate the lack of a pharmacological and psychological treatment with high success rates, which highlights the importance of exploring potential psychosocial interventions for the treatment of CUD. Given the evidence of psilocybin's therapeutic potential in the treatment of substance use disorders (de Veen et al., 2017), we aim to conduct a study using psilocybin-assisted-psychotherapy in the treatment of CUD. The study aims to evaluate the feasibility, safety, tolerability and potential therapeutic effect of 2 doses \[25 mg\] of psilocybin administered as part of an 8-week Motivational Enhancement Therapy (MET) and supportive therapy. This trial will be the first to evaluate the potential treatment effects of psilocybin on symptoms of CUD.

Conditions

Interventions

TypeNameDescription
DRUGPsilocybin combined with PsychotherapyThe intervention consists of a 9-week treatment protocol that is based on supportive psychotherapy and Motivational Enhancement Therapy. Overall, the therapy course includes 8 motivational enhancement therapy sessions and two experimental drug sessions.

Timeline

Start date
2025-03-01
Primary completion
2026-03-01
Completion
2026-06-01
First posted
2024-01-25
Last updated
2025-03-19

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT06225232. Inclusion in this directory is not an endorsement.